Glucagon-like peptide-1 receptor agonists, diabetes, obesity, and psoriasis

VernacularTitle:胰升糖素样肽1受体激动剂与糖尿病、肥胖和银屑病
Author: Jingyan TIAN ; Mingdao CHEN
Publication Type:Journal Article
Keywords: Glucagon-like peptide-1; Psoriasis; Inflammation; Diabetes mellitus; Obesity
From: Chinese Journal of Endocrinology and Metabolism 2012;28(4):255-257
CountryChina
Language:Chinese
Abstract: More and more extrapancreatic actions of incretin-based therapies have been demonstrated and recently case reports have linked glucagon-like peptide-1 (GLP-1) receptor agouist therapy with the improvements in psoriasis.Psoriasis is a common skin disorder characterized by chronic inflammation.Epideminological studies have showed that patients with psoriasis exhibit increased rates of cardiovascular disease,obesity,and type 2 diabetes,owing probably to the enhanced local and (or) systemic inflammation.The observations of anti-inflammatory actions of GLP-1,which exerts direct and indirect actions on immune function,together with the improved psoriasis,offer new insights into the investigation of non-classical anti-inflammatory actions of incretin-based therapeutics and provide a new direction for the research of the novel clinical application of GLP-1.